| NCT ID | NCT03719690 |
| Title | Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy (AIM-HN/SEQ-HN) |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | Kura Oncology, Inc. |
| Indications |
head and neck squamous cell carcinoma |
| Therapies | |
| Age Groups: | adult senior |